Emalex Biosciences advances Tourette syndrome strategy as ecopipam delays relapse in Phase 3 trial
D1 receptor targeting may change Tourette syndrome care. Ecopipam’s Phase 3 data now face the bigger test: regulation and adoption.
Pharma & Biotech